[1]
|
Chen, Y., Zhu, S., Liu, T., Zhang, S., Lu, J., Fan, W., et al. (2023) Epithelial Cells Activate Fibroblasts to Promote Esophageal Cancer Development. Cancer Cell, 41, 903-918.e8. https://doi.org/10.1016/j.ccell.2023.03.001
|
[2]
|
Wen, T., Wang, W. and Chen, X. (2022) Recent Advances in Esophageal Squamous Cell Precancerous Conditions: A Review. Medicine, 101, e32192. https://doi.org/10.1097/md.0000000000032192
|
[3]
|
Sheikh, M., Roshandel, G., McCormack, V. and Malekzadeh, R. (2023) Current Status and Future Prospects for Esophageal Cancer. Cancers, 15, Article 765. https://doi.org/10.3390/cancers15030765
|
[4]
|
Zhu, H., Ma, X., Ye, T., Wang, H., Wang, Z., Liu, Q., et al. (2022) Esophageal Cancer in China: Practice and Research in the New Era. International Journal of Cancer, 152, 1741-1751. https://doi.org/10.1002/ijc.34301
|
[5]
|
Silva, M.L.S. (2015) Cancer Serum Biomarkers Based on Aberrant Post-Translational Modifications of Glycoproteins: Clinical Value and Discovery Strategies. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1856, 165-177. https://doi.org/10.1016/j.bbcan.2015.07.002
|
[6]
|
Zhong, L., Li, H., Chang, W., Ao, Y., Wen, Z. and Chen, Y. (2023) TP53 Mutations in Esophageal Squamous Cell Carcinoma. Frontiers in Bioscience-Landmark, 28, Article 219. https://doi.org/10.31083/j.fbl2809219
|
[7]
|
Sabapathy, K. and Lane, D.P. (2019) Corrigendum to ‘Understanding P53 Functions through P53 Antibodies’. Journal of Molecular Cell Biology, 11, 1105-1105. https://doi.org/10.1093/jmcb/mjz110
|
[8]
|
Yang, T., Hui, R., Nouws, J., Sauler, M., Zeng, T. and Wu, Q. (2022) Untargeted Metabolomics Analysis of Esophageal Squamous Cell Cancer Progression. Journal of Translational Medicine, 20, Article No. 127. https://doi.org/10.1186/s12967-022-03311-z
|
[9]
|
马广婷. 细节护理在消化内科护理中的应用探析[J]. 临床检验杂志(电子版), 2019, 8(3): 180-181.
|
[10]
|
Ma, D., Zhang, Y., Shao, X., Wu, C. and Wu, J. (2022) PET/CT for Predicting Occult Lymph Node Metastasis in Gastric Cancer. Current Oncology, 29, 6523-6539. https://doi.org/10.3390/curroncol29090513
|
[11]
|
Withey, S.J., Goh, V. and Foley, K.G. (2022) State-of-the-Art Imaging in Oesophago-Gastric Cancer. The British Journal of Radiology, 95, Article 20220410. https://doi.org/10.1259/bjr.20220410
|
[12]
|
Finkenzeller, T., Zorger, N., Kühnel, T., Paetzel, C., Schuierer, G., Stroszczynski, C., et al. (2012) Novel Application of T1-Weighted BLADE Sequences with Fat Suppression Compared to TSE in Contrast-Enhanced T1-Weighted Imaging of the Neck: Cutting-Edge Images? Journal of Magnetic Resonance Imaging, 37, 660-668. https://doi.org/10.1002/jmri.23843
|
[13]
|
Wang, Y., Mukkamalla, S.K.R., Singh, R., Babiker, H.M. and Lyons, S. (2024) Esophageal Cancer. StatPearls Publishing.
|
[14]
|
Xiang, G., Xu, C., Chai, G., Lyu, B., Li, Z., Wang, B., et al. (2023) Re-Irradiation for Local Primary-Recurrence Esophageal Squamous Cell Carcinoma Treated with IMRT/VMAT. Radiation Oncology, 18, Article No. 114. https://doi.org/10.1186/s13014-023-02265-w
|
[15]
|
Laios, K., Apostolou, K.G., Vavlas, A., Ntousopoulos, A., Chrysikos, D., Troupis, T., et al. (2023) The History of Esophageal Surgery. Acta Chirurgica Belgica, 123, 712-723. https://doi.org/10.1080/00015458.2023.2254604
|
[16]
|
杨泽波, 张媛媛, 胡旭. 食管鳞癌Mckeown微创与开放手术的疗效分析[J]. 巴楚医学, 2023, 6(3): 100-104.
|
[17]
|
Lu, Z., Wang, J., Shu, Y., Liu, L., Kong, L., Yang, L., et al. (2022) Sintilimab versus Placebo in Combination with Chemotherapy as First Line Treatment for Locally Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ORIENT-15): Multicentre, Randomized, Double Blind, Phase 3 Trial. British Medical Journal, 377, e068714. https://doi.org/10.1136/bmj-2021-068714
|
[18]
|
Sun, J.M., Shen, L., Shah, M.A., Enzinger, P., et al. (2021) KEYNOTE-590 Investigators. Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomized, Placebo-Controlled, Phase 3 Study. The Lancet, 398, 759-771. https://doi.org/10.1016/S0140-6736(21)01234-4
|
[19]
|
Xu, J., Kato, K., Raymond, E., Hubner, R.A., et al. (2023) Tislelizumab plus Chemotherapy versus Placebo plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (RATIONALE-306): A Global, Randomized, Placebo-Controlled, Phase 3 Study. The Lancet Oncology, 24, 483-495. https://doi.org/10.1016/S1470-2045(23)00108-0
|
[20]
|
Weidenbaum, C. and Gibson, M.K. (2022) Approach to Localized Squamous Cell Cancer of the Esophagus. Current Treatment Options in Oncology, 23, 1370-1387. https://doi.org/10.1007/s11864-022-01003-w
|
[21]
|
Harada, K., Rogers, J.E., Iwatsuki, M., Yamashita, K., Baba, H. and Ajani, J.A. (2020) Recent Advances in Treating Oesophageal Cancer. F1000Research, 9, 1189. https://doi.org/10.12688/f1000research.22926.1
|
[22]
|
An, L., Li, M. and Jia, Q. (2023) Mechanisms of Radiotherapy Resistance and Radiosensitization Strategies for Esophageal Squamous Cell Carcinoma. Molecular Cancer, 22, Article No. 140. https://doi.org/10.1186/s12943-023-01839-2
|
[23]
|
Puhr, H.C., Preusser, M. and Ilhan-Mutlu, A. (2021) Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021? Cancers, 13, Article 4632. https://doi.org/10.3390/cancers13184632
|
[24]
|
Wei, D.D., Fang, J.M., Wang, H.Z., Chen, J., Kong, S., Jiang, Y., et al. (2024) Perioperative Immunotherapy for Esophageal Squamous Cell Carcinoma. Frontiers in Immunology, 15, Article 1330785. https://doi.org/10.3389/fimmu.2024.1330785
|
[25]
|
Huang, Z., Ma, X., Zhang, J., Li, X., Lai, N. and Zhang, S. (2018) Cetuximab for Esophageal Cancer: An Updated Meta-Analysis of Randomized Controlled Trials. BMC Cancer, 18, Article No. 1170. https://doi.org/10.1186/s12885-018-5040-z
|
[26]
|
Yang, Y., Hong, P., Xu, W.W., He, Q. and Li, B. (2020) Advances in Targeted Therapy for Esophageal Cancer. Signal Transduction and Targeted Therapy, 5, Article No. 229. https://doi.org/10.1038/s41392-020-00323-3
|